Abstract
Opioid maintenance treatment with methadone or buprenorphine is an established first-line treatment for opioid dependence. In addition to the novel weekly and monthly subcutaneously injectable buprenorphine depot CAM 2038 (Buvidal (R)), which is already available in Germany, two other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade (TM)) and a 6-month buprenorphine depot implant (Probuphine (TM)). Basic pharmacological and clinical data of these three medications are given and possible clinical applications are discussed.
| Item Type: | Journal article |
|---|---|
| Faculties: | Medicine |
| Subjects: | 600 Technology > 610 Medicine and health |
| ISSN: | 0028-2804 |
| Language: | German |
| Item ID: | 79253 |
| Date Deposited: | 15. Dec 2021 14:47 |
| Last Modified: | 15. Dec 2021 14:47 |
Actions (login required)
- View Item
